Effects of small-particle aerosols of local anaesthetic on dyspnoea in patients with respiratory disease.
This study was devised to test the hypothesis that dyspnoea could be mediated by unmyelinated vagal sensory nerve endings (type J receptors) situated at alveolar level in the lung. A modified jet nebulizer was used to generate an aerosol of local anaesthetic in particles small enough to allow alveolar deposition. Lignocaine (2% and 5%) produced aerosols with an arithmetic mean diameter (+/- SD) of 1.5 +/- 0.3 and 1.2 +/- 0.6 micron respectively, the mass median diameters being 1.7 (geometric standard deviation = 1.2) and 2.5 (geometric standard deviation = 1.7) micron respectively. In experimental animal models a vagally mediated tachypnoea may be induced acutely by pulmonary microembolism. This response is known to be mediated by unmyelinated pulmonary afferent nerves in the vagus. Local anaesthetic agents administered as small particles, but not as large particles, obtunded this response, which suggests that the aerosol was capable of penetration to alveolar level. Upon this background, a clinical study was designed to compare the effects of lignocaine with placebo both given as small-particle aerosols. Six patients, including two with diffuse alveolar pathology and four with chronic airflow obstruction, were studied. Respiratory frequency was determined before and after the aerosol, and exercise tolerance and breathlessness were measured with a 6 min walking test and visual analogue scales. After lignocaine there was no clinical evidence of anaesthesia of the upper airways but bronchoconstriction occurred. While no overall effect of lignocaine on dyspnoea was apparent, individual patients showed some evidence of benefit.(ABSTRACT TRUNCATED AT 250 WORDS)
D000336:Aerosols; D000368:Aged; D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004417:Dyspnea / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000503:physiopathology; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012140:Respiratory Tract Diseases / Q000188:drug therapy* / Q000503:physiopathology; D012996:Solutions
D000336:Aerosols; D012996:Solutions; D008012:Lidocaine